April 12th 2021
Richard Gorlick, MD, discussed results from a study examining the use of integrative surfaceome profiling to identify immunotherapeutic targets in patients with osteosarcomas.
April 9th 2021
Jonathan C. Trent, MD, PhD, discusses the role of avapritinib in PDGFRA exon 18–positive gastrointestinal stromal tumor.
April 8th 2021
Erin Murphy, MD, discusses remaining questions with stereotactic body radiotherapy in pediatric sarcoma.
April 8th 2021
Encouraging efficacy data for ripretinib as a later-line therapy for patients with advanced gastrointestinal stromal tumor have investigators hypothesizing new approaches to derive even greater benefit with the agent.
April 7th 2021
Erin Murphy, MD, discusses the clinical implications of pazopanib plus stereotactic body radiotherapy in pediatric sarcoma.
April 6th 2021
Erin Murphy, MD, discusses future research efforts with pazopanib plus stereotactic body radiation therapy in patients with pediatric sarcoma.
April 5th 2021
Michael Wagner, MD, discusses the rationale for using immunotherapy in the treatment of patients with angiosarcoma.
March 30th 2021
The FDA has granted a fast track designation for annamycin as a treatment for patients with soft tissue sarcoma lung metastases.
March 19th 2021
Jonathan C. Trent, MD, PhD, discusses the utility of circulating tumor DNA to understand primary driver mutations in gastrointestinal stromal tumor.